Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cardiac PET/CT can guide CAD therapy

Key clinical point: Determination of PET/CT-derived myocardial ischemic burden is useful in deciding upon the optimal CAD management strategy.

Major finding: Patients with symptomatic CAD and an ischemic burden greater than 10% had a 4.6-fold greater risk of MACE if managed medically than by revascularization.

Study details: This was a retrospective single-center study of 5,528 consecutive patients with symptomatic CAD who underwent PET/CT to determine the size of their myocardial ischemic burden.

Disclosures: The presenter reported having no financial conflicts regarding his study, conducted free of commercial sponsorship.

Citation:

REPORTING FROM ACC 19